AIM ImmunoTech Inc.
Price data unavailable
Track AIM in your trading journalAbout AIM ImmunoTech Inc.
AIM ImmunoTech Inc. (AIM) is a publicly traded US company. AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
The company reports trailing twelve-month revenue of $22,000 and net loss of $3.02M.
Key metrics include a return on equity of -142.3%, a debt-to-equity ratio of 3.04.
Investors tracking AIM can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.
Fundamentals
| Revenue (TTM) | $22,000 |
| Net Income (TTM) | $-3.02M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -142.26% |
| Debt-to-Equity | 3.04 |
| Dividend per Share | — |
Recent News
Want real-time analysis on AIM?
Track it free in your trading journal. Log trades, tag setups, and review your edge.